Wearable Microfluidic Systems for Measuring Sweat Biomarkers in Cystic Fibrosis Patients During Exercise in Remote Settings

可穿戴微流体系统用于测量囊性纤维化患者在远程锻炼期间的汗液生物标志物

• 批准号: 10383275
• 负责人: Stephen Peter Lee
• 金额: $ 29.99万
• 依托单位: EPICORE BIOSYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-05 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10383275
• 关键词: Address; Adult; Biological Markers; Blood Plasma Volume; Bronchiectasis; Caring; Cell membrane; Cellular Phone; Chlorides; Chronically Ill; Clinic; Clinical; Collection; Computer software; Custom; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Data; Dehydration; Devices; Diabetes Mellitus; Disease; Electrolytes; Environment; Equipment; Excretory function; Exercise; Exhibits; Foundations; Future; Health; Heart Rate; Home; Hydration status; Impairment; Individual; Laboratories; Lead; Liquid substance; Malnutrition; Measurement; Measures; Mental Depression; Microfluidic Microchips; Microfluidics; Movement; Multicenter Studies; Mutation; Nutrient; Obesity; Osteoporosis; Patients; Performance; Physical Exercise; Physiological; Physiology; Pilocarpine; Pilot Projects; Play; Regimen; Regulator Genes; Reporting; Rest; Role; Sampling; Serum; Skin; Sodium; Sodium Chloride; Strenuous Exercise; Study Subject; Sweat Glands; Sweating; System; Techniques; Testing; Time; Universities; Water; Work; base; children with cystic fibrosis; cohort; cystic fibrosis patients; exercise capacity; exercise intensity; experience; falls; healthy volunteer; high risk; image processing; insight; medical schools; novel; patient population; pediatric patients; prototype; response; sensor; smartphone Application; temporal measurement; tool; wearable platform; wearable sensor technology

Abstract: Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which lead to impaired chloride (Cl-) movement across the plasma membrane. Individuals with CF typically excrete sweat with substantially higher Cl- and sodium (Na+) concentrations than healthy individuals. CF can lead to multi-organ manifestations, either primarily or secondarily (i.e. bronchiectasis, diabetes mellitus, osteoporosis, malnutrition, depression). Exercise is recommended as adjunctive treatment for many of these manifestations and exercise capacity has been shown to be an independent factor in CF survival. With the recent approval of highly effective CFTR modulators (HEMT) for 90% of CF patients, it is likely that survival for CF patients will increase substantially and it is anticipated that many patients will survive into their sixties. The efficacy of HEMT has led to some unintended consequences such as that some patients have become obese (BMI>30) and many have become less adherent to their daily airway clearance regimen and rely on exercise for airway clearance. These factors underscore the importance that regular vigorous exercise will play in ongoing care of CF patients, which is now expected to last many more decades. Since excessive water and electrolyte losses can contribute to dehydration and electrolyte imbalance, CF patients are at high risk for severe dehydration and electrolyte loss which can have deleterious consequences and limit intensity of exercise. There is substantial data that has described sweat rates and electrolyte loss in response to exercise in normal athletes, however, there is limited data for CF patients. We recently reported a novel skin-interfaced wearable microfluidic device and smartphone image processing platform that enables analysis of regional sweating rate and sweat chloride loss in athletes and CF pediatric patients in a mode that is comfortable and imperceptible to the wearer. We hypothesize that continuous electrolyte and sweat rate measurements captured with our soft wearable microfluidic sensors and smartphone application (called the CF Patch System) will provide actionable hydration and electrolyte repletion information for adult CF patients during exercise. The CF Patch wearable platform offers a groundbreaking approach for the quantitative and continuous assessment of CF hydration and health conditions. The foundational insights from this work will enable new care management paradigms for CF patients in remote settings.

抽象的： 囊性纤维化（CF）是由囊性纤维化跨膜电导调节剂（CFTR）突变引起的 导致氯化物（CL-）运动跨质膜的基因。 CF通常 与健康个体相比，排泄汗液的Cl-和钠（Na+）浓度要高得多。 CF可以领导 主要或第二（即支气管扩张，糖尿病，骨质疏松症，骨质疏松症， 营养不良，抑郁）。建议运动作为许多这些表现的辅助治疗 运动能力已被证明是CF存活的独立因素。随着最近的批准 90％的CF患者的高效CFTR调节剂（HEMT），CF患者的生存很可能 大幅增加，预计许多患者将生存到六十多岁。 Hemt的功效 导致了一些意想不到的后果，例如某些患者变得肥胖（BMI> 30），许多患者 已经变得不太遵守其日常气道通关方案，并依靠运动进行气道通关。 这些因素强调了定期剧烈运动在CF患者持续护理中的重要性， 现在预计将持续数十年。由于水和电解质损失过多会导致 为了脱水和电解质不平衡，CF患者有严重脱水和电解质损失的高风险 可以带来有害后果并限制运动强度。有大量数据具有 描述了正常运动员运动的汗水率和电解质损失，但是有限 CF患者的数据。我们最近报道了一种新型的皮肤脱落的可穿戴微流体设备和智能手机 图像处理平台可以分析运动员的区域出汗率和汗水损失 以及CF儿科患者的佩戴者舒适且无法察觉的模式。我们假设这一点 连续的电解质和汗液速率测量用我们的柔软可穿戴微流体传感器捕获的 智能手机应用程序（称为CF补丁系统）将提供可操作的水合和电解质补充 运动过程中成人CF患者的信息。 CF补丁可穿戴平台提供了开创性的 对CF水合和健康状况进行定量和连续评估的方法。这 这项工作的基本见解将为CF患者提供新的护理管理范例 设置。